|
You are here:
Education & Tools
>
|
|
 |
 Conference Highlights |
Antifungal Agents
-
SAFETY AND EFFICACY OF AMBISOME IN PATIENTS WITH FUNGAL INFECTIONS.
A POST MARKETING MULTICENTRE SURVEILLANCE STUDY IN TURKEY.
Anak S and the PMS Study Group
Istanbul University- School of Medicine, Dept. of Pediatric Hematology/Oncology/BMT, çapa Istanbul, Turkey
-
ASSESSMENT OF THE PHARMACOKINETICS (PK) OF ANIDULAFUNGIN (ANID) IN PATIENTS WITH INVASIVE ASPERGILLOSIS (IA) RECEIVING CONCOMITANT LIPOSOMAL AMPHOTERICIN B (LAMB).
Dowell J, Schranz J, Stogniew M, Krause D, Henkel T King of Prussia, USA
-
SAFETY AND EFFECTIVENESS OF HIGH DOSE/LONG DURATION ABLC THERAPY
Hooshmand-Rad R1, Reed MD2, Chu A1, Gotz V1, Morris JA1, Batty S3, Dominguez EA4
1ProSanos Corporation, La Jolla, USA;
2School of Medicine, Department of Pediatrics, Case Western Reserve University, Cleveland, USA;
3ENZON Pharmaceuticals, Bridgewater, USA; 4Department of Medicine, Section of Infectious Diseases, University of Nebraska Medical Center, Omaha, USA
-
USE OF AMPHOTERICIN B LIPID COMPLEX (ABLC) IN PATIENTS OVER 65 YEARS
Hooshmand-Rad R1, Chu A1, Gotz V1, Morris JA1, Batty S2, Freifeld A 3
1ProSanos Corporation, La Jolla, USA;
2ENZON Pharmaceuticals, Bridgewater, USA;
3Department of Medicine, University of Nebraska Medical Center, Omaha, USA
-
ORAL DELIVERY OF AMPHTERICIN B COCHLEATES: DEVELOPMENTAL STATUS
Mannino RJ1, Ahl PL1, Delmarre D1, Fogerite SG1, Ngoje J1, Tan F1,
Lu R1, Sandulow J1, Kalbag S1, Machado H2, Mumper R2, Delmas G3 and Perlin D3
1BioDelivery Sciences International, Inc., Newark, USA
2Center for Pharmaceutical Science and Technology, University of Kentucky, Lexington, USA
3Public Health Research Institute at the International Center for Public Health, Newark, USA
-
ANTIFUNGAL PROPHYLAXIS IN 771 PATIENTS (PTS) WITH HEMATOLOGICAL MALIGNANCIES: IS THERE A PERFECT DRUG ?
Mattiuzzi G, Alvarado G, Zhou X, Giles FJ, Bekele BN, Estey E and Kantarjian H
The University of Texas M.D. Anderson Cancer Center. Houston, USA
-
EVALUATING EFFICACY OF SYSTEMIC ANTIFUNGALS FOR ESOPHAGEAL CANDIDIASIS: A COMPARISON OF CLINICAL TRIAL DESIGNS
Navarro E, Dixon C, Powers JH
Office of Drug Evaluation IV, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, USA
-
CASPOFUNGIN HEPATOTOXICITY AND CLINICAL EXPERIENCE IN AN ORGAN TRANSPLANT POPULATION
Simoneau E1, Poirier C2, Mendola A3 and Lemieux C1
1Dept of Microbiology-Infectious Diseases,
2Dept of Medecine and
3Dept of Pharmacy, Hôpital Notre-Dame du CHUM and Université de Montreal, Montreal, Canada
-
TWICE WEEKLY FLUCONAZOLE PROPHYLAXIS FOR PREVENTION OF INVASIVE FUNGAL INFECTION IN HIGH-RISK PRETERM INFANTS LESS THAN 1000 GRAMS.
Kaufman D1, Boyle R 1, Hazen KC2, Patrie JT 3, Robinson M1 and Grossman LB1.
1Pediatrics;
2Pathology and Microbiology and 3Biostatistics, University of Virginia, Charlottesville, USA
-
ELIMINATION OF ASPERGILLUS AS A SIGNIFICANT PATHOGEN IN AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PROGRAM AFTER INTRODUCTION OF ROUTINE LONG-TERM ITRACONAZOLE PROPHYLAXIS.
Winston DJ, Emmanouilides C, Bartoni K, Schiller GJ, Paquette R, Territo M
Stem cell Transplant Program/Department of Medicine, UCLA Medical Center, Los Angeles, USA
|
|